LRI Investments LLC Trims Stock Holdings in Kenvue Inc. (NYSE:KVUE)

LRI Investments LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,881 shares of the company’s stock after selling 1,351 shares during the quarter. LRI Investments LLC’s holdings in Kenvue were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $29,000. SRS Capital Advisors Inc. raised its stake in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Asset Planning Inc purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $42,000. Finally, Clarity Asset Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 1.7%

Kenvue stock opened at $24.47 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market capitalization of $46.95 billion, a price-to-earnings ratio of 46.17, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The stock’s fifty day moving average is $23.13 and its two-hundred day moving average is $22.55.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue’s revenue was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 earnings per share. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KVUE. Evercore ISI began coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price target for the company. Citigroup increased their price objective on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research report on Friday. Barclays cut their price objective on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, April 14th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, UBS Group increased their price objective on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Friday. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.25.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.